greeksoup/ stock research

PAVmed Inc.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 15 May 2026: press release. The quarter’s numbers.

Key takeaways

  • Operating expenses rose to $8.1 million: Operating expenses were about $8.1 million, including $0.2 million of stock-based compensation, compared with $6.9 million in the prior quarter. Source
  • GAAP net loss per share $(4.42): Net loss attributable to common stockholders was about $7.0 million, or $(4.42) per diluted share, compared with $1.8 million, or $(2.05), in the prior quarter. Source
  • Non-GAAP adjusted loss $(1.17) per share: The non-GAAP adjusted loss was about $1.9 million, or $(1.17) per share, compared with $0.9 million, or $(1.05), in the prior quarter. Source
  • Cash rose to $6.5 million: Cash and cash equivalents were $6.5 million at March 31, 2026, up from $1.5 million at December 31, 2025. Source
  • EsoGuard revenue and volume below prior quarter: EsoGuard revenue and tests processed were below the prior quarter, which reported $1.5 million of revenue and 3,664 tests. Source
  • Implantable monitor nearing presubmission: Presubmission and testing for the implantable physiological monitor are expected to begin soon, ahead of a planned FDA 510(k) submission. Source
  • Lucid pro forma cash of $45 million: Lucid ended the first quarter with $45 million of pro forma cash, which the release links to a runway into 2027. Source

“PAVmed now has a significantly simplified capital structure and strengthened balance sheet, positioning the Company to focus on execution across our core businesses and evaluate additional asset acquisition opportunities aligned with our long-term growth strategy,”

Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
Cash runway (Lucid Diagnostics) Sourceinto 2027into 2027

What changed from last quarter

  • New: Lucid completed an underwritten public offering of common stock, netting about $17 million in proceeds, per the release. Source
  • New: Joseph Virgilio is assuming broader responsibilities beyond the Chief Business Officer of Medical Devices role he was appointed to in the prior quarter. Source
  • New: PAVmed reports that it is evaluating additional acquisition candidates for its portfolio, a topic not covered in the prior release. Source

Results and cash position

  • Operating expenses rose to $8.1 million: Operating expenses were about $8.1 million, including $0.2 million of stock-based compensation, compared with $6.9 million in the prior quarter. Source
  • GAAP net loss per share $(4.42): Net loss attributable to common stockholders was about $7.0 million, or $(4.42) per diluted share, compared with $1.8 million, or $(2.05), in the prior quarter. Source
  • Non-GAAP adjusted loss $(1.17) per share: The non-GAAP adjusted loss was about $1.9 million, or $(1.17) per share, compared with $0.9 million, or $(1.05), in the prior quarter. Source
  • Cash rose to $6.5 million: Cash and cash equivalents were $6.5 million at March 31, 2026, up from $1.5 million at December 31, 2025. Source

Lucid Diagnostics and EsoGuard

  • EsoGuard revenue and volume below prior quarter: EsoGuard revenue and tests processed were below the prior quarter, which reported $1.5 million of revenue and 3,664 tests. Source
  • Presence at Digestive Disease Week: Lucid reported multiple EsoGuard abstracts and wide engagement with gastroenterologists at the Digestive Disease Week meeting. Source
  • Guideline update previewed at meeting: A major upcoming clinical practice guideline update was previewed, recommending EsoGuard and EsoCheck as the only non-endoscopic test with high certainty of evidence. Source

“Veris continues to expand its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission, and Lucid continues to build commercial momentum for EsoGuard with a strengthened balance sheet pending Medicare coverage.”

Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer

Veris Health and OSU James

  • OSU James commercial phase underway: Veris said the commercial phase with The Ohio State University’s James Cancer Hospital is underway. Source
  • Expansion into more departments: Expansion into additional departments is in progress, and the release reports clinical and administrative feedback from the hospital. Source
  • Implantable monitor nearing presubmission: Presubmission and testing for the implantable physiological monitor are expected to begin soon, ahead of a planned FDA 510(k) submission. Source

Medical device portfolio

  • Device programs progressed under Virgilio: Multiple device programs progressed, including the PortIO implantable intraosseous vascular access device and Duke-licensed endoscopic esophageal imaging technology. Source
  • Virgilio oversees development and commercialization: Joseph Virgilio oversees development and commercialization of the current and future device portfolio. Source
  • Multiple technologies being advanced: Management said it is actively advancing multiple technologies within the relaunched device portfolio. Source

“We are also actively advancing multiple technologies within our relaunched medical device portfolio under Joseph Virgilio’s leadership, while increasingly leveraging his experience building and scaling growth-stage businesses.”

Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer

Costs and non-cash items

  • Non-cash items adjusted in reconciliation: The reconciliation adjusts for a $(3.3) million change in fair value of convertible debt and a $3.4 million loss on debt extinguishment, both in other income and expenses. Source
  • Stock issued for operating expenses: Operating expenses issued in stock were $1.95 million, compared with $0.05 million a year earlier, and are excluded from the non-GAAP measure. Source
  • Preferred dividends reconciled to common loss: Preferred stock dividends and deemed dividends were $6.9 million in the reconciliation, compared with $1.3 million a year earlier. Source

Capital and balance sheet

  • Lucid pro forma cash of $45 million: Lucid ended the first quarter with $45 million of pro forma cash, which the release links to a runway into 2027. Source
  • Simplified capital structure described: Management described a significantly simplified capital structure and a strengthened balance sheet across the company. Source
  • Lucid offering netted about $17 million: Lucid completed an underwritten public offering of common stock, with proceeds netting about $17 million. Source

Strategy and acquisitions

  • Focus on execution across core businesses: Management said the balance sheet positions the company to focus on execution across its core businesses. Source
  • EsoGuard Medicare coverage still pending: Lucid continues to build commercial momentum for EsoGuard while Medicare coverage is pending; the release gives no date for it. Source
  • Acquisition evaluation ongoing: PAVmed says it is evaluating additional asset acquisitions aligned with its long-term growth strategy. Source

Coming up, as management said on 15 May 2026

  • Presubmission and testing to begin soon: Presubmission and testing activities for the implantable physiological monitor are expected to begin soon, in support of a planned FDA 510(k) submission. Source
  • Medicare coverage for EsoGuard pending: Lucid’s EsoGuard is awaiting Medicare coverage. The release does not give a timing for the coverage decision. Source

Figures management reported

FigureReported
EsoGuard tests processed, 1Q26 Source3,177
EsoGuard revenue recognized, 1Q26 Source$1.3 million

Earlier plans management reported on

  • Not stated: The release refers to a planned FDA 510(k) submission but gives no date. The prior release had given a late 2026 timing. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.